Mereo BioPharma (Biopharma, Biotechnology) — Funding, Investors & Signals 2026

Mereo BioPharma

Mereo BioPharma is a clinical-stage company focused on developing & commercialising rare disease & oncology treatments.

Founded 2015

London, United Kingdom 45 employees Post Ipo Equity Total: $373.90M Biopharma, Biotechnology +1

Mereo Biopharma is a clinical-stage company focused on developing and commercializing rare disease and oncology treatments. Since its founding in 2015, the company has demonstrated an agile and purpose-driven approach to bring novel therapies to market. Through acquisitions from Novartis and AstraZeneca, and a merger with OncoMed, Mereo has expanded its pipeline to address critical needs in Osteogenesis Imperfecta (OI), Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD), and oncology. The company's $50.00M Post-IPO Equity investment on June 14, 2024 included participation from prominent investors such as Deerfield Management, Janus Handerson, Perceptive Advisors, Rock Springs Capital, Frazier Life Sciences, and Rubric Capital Management. This strong financial backing reflects confidence in Mereo's mission and approach. Mereo's commitment to leveraging the power of science to create new therapeutic possibilities, combined with its focused and agile methodology, has enabled the company to advance two therapies from in-licensing to Phase 3 studies in under 5 years. This rapid progress underscores the team's dedication to addressing the unmet needs of patients with rare diseases and oncological conditions. The company's headquarters in the United Kingdom serves as a strategic hub for its operations. By attracting talented individuals with a passion for improving healthcare and a deep understanding of navigating complex reimbursement processes, Mereo is well-positioned to continue its journey of collaboration and innovation in the field of rare diseases. Follow Mereo Biopharma's remarkable progress as it forges new paths in the rare disease arena.

Funding Stage	Amount	Investors	Lead Investors	Date
Post-IPO Equity	$50.00M	6	Rubric Capital Management	14 Jun 2024
Post-IPO Equity	$100.10M	-		10 Feb 2021
Post-IPO Equity	$70.00M	10	Surveyor Capital	04 Jun 2020
Post-IPO Debt	£20.00M	2	Silicon Valley Bank	25 Sep 2017
Post-IPO Equity	£14.80M	-		09 Jun 2016

Funding Stage

Amount

Investors

Lead Investors

Date

Post-IPO Equity

$50.00M

Rubric Capital Management

14 Jun 2024

Post-IPO Equity

$100.10M

10 Feb 2021

Post-IPO Equity

$70.00M

Surveyor Capital

04 Jun 2020

Post-IPO Debt

£20.00M

Silicon Valley Bank

25 Sep 2017

Post-IPO Equity

£14.80M

09 Jun 2016

FAQ About Mereo BioPharma

Mereo BioPharma is a clinical-stage company focused on developing & commercialising rare disease & oncology treatments.

Mereo BioPharma was founded in 2015.

Mereo BioPharma is headquartered in London, United Kingdom.

Mereo BioPharma operates in the following industries: Biopharma, Biotechnology, Health Care.

Mereo BioPharma has approximately 45 employees.

Mereo BioPharma has completed 6 funding rounds, raising a total of $373.90M. The latest funding stage is Post Ipo Equity.

Top alternatives and competitors to Mereo BioPharma include Alnylam Pharmaceuticals, Apollo Therapeutics, Surface Oncology Inc., OCEAN BIOMEDICAL. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Mereo BioPharma and Alnylam Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Mereo BioPharma

General Information

Track Mereo BioPharma

Discover More

About Mereo BioPharma

Funding Rounds & Investors (6)

Mereo BioPharma Alternatives & Competitors

FAQ About Mereo BioPharma

Don't just browse. Track.